Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine, Venetoclax, and Olutasidenib in IDH1-mutated AML and MDS
NCT06445959Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2024
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of olutasidenib, venetoclax, decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2024; status: recruiting.
02
Drugs
olutasidenibvenetoclaxdecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06445959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445959.